There are many possible complications associated with the concomitant use of herbs and medications, but limited information is available on herb-herb or herb-drug interactions. Paederia foetida Linn. (family: Rubiaceae) is utilized in the Indian traditional medicine. It exhibits various pharmacological properties, such as antidiabetic, analgesic, anti-inflammatory, antimicrobial, hepatoprotective, anthelmintic, antiulcer and antioxidant activities. The purpose of the present work was to investigate the inhibitory potential of the P. foetida ethanolic extract and its bioactive constituent lupeol on hepatic phase I drug metabolizing enzymes. The high performance thin layer chromatography was performed for qualitative analysis of various extracts of P. foetida. The effects of P. foetida extract on rat liver microsomes (RLMs) and individual cytochrome P-450 (CYP) isozymes (CYP3A4 and CYP2D6) were investigated using CYP450-carbon monoxide complex assay and fluorescence microplate assay, respectively. The ethanolic extract and lupeol (both at a concentration of 100 μg/mL) showed 45±3.3 and 44±3.8% inhibition of rat liver microsomes, respectively, which were significantly less than that of known inhibitor ketoconazole (74±5.4% inhibition at 100 μg/mL). The 50% inhibitory concentrations (IC 50 ) of ethanolic extract on CYP3A4 and CYP2D6 were 78±2.3 and 82±3.1 µg/mL, respectively, whereas its major bioactive constituent lupeol has IC 50 values of 83±2.0 and 84±2.6 µg/mL for CYP3A4 and CYP2D6, respectively. The results were of lesser magnitude compared to known inhibitors, ketoconazole and quinidine, respectively. The current study revealed that P. foetida has less inhibitory potential in comparison to that of known inhibitors, ketoconazole and quinidine, on two major drug metabolizing isozymes, CYP3A4 and CYP2D6. Thus, the use of P. foetida as a complementary or alternative medicine may be safe in regard to herb-drug interactions.
Paederia foetida Linn. (family: Rubiaceae) is known as "prasarini" in Sanskrit in India. It is an extensive foetid-smelling perennial climber. The plant grows in most parts of India and throughout the Malayan Archipelago, extending from Mauritius northward to China and Japan. The whole plant is specifically recommended for the treatment of rheumatoid arthritis [1] . Leaf juice of the plant is astringent and also given to children with diarrhea [2] . A decoction of the leaves acts as diuretic [3] and the roots and barks are used as emetic and in the treatment of piles, inflammation of the spleen and pain in the chest and liver [4] . The fruit is used to alleviate toothache [5] . This plant is known to exhibit several pharmacological activities, such as analgesic, anti-inflammatory [6, 7] , antioxidant [8, 9] , antidiabetic [10] , antimicrobial [11] [12] [13] , anthelmintic [14] , hepatoprotective [15] , antiulcer [16] actions. Previous phytochemical investigation showed that the leaves contain methyl mercaptan and aerial parts contain paederolone, paederone and β-sitosterol [5, 17] . Additionally, several parts of this plant contain various compounds, such as hentriacontane, hentriacontanol, ceryl-alcohol and ursolic acid [18] .
The combination regimen using multi-drug therapy is utilized to restore health more effectively [19] . To assure a good patient care, it is important that there should be an awareness of possible health complications associated with the concomitant use of herbs and medications [20] . A large number of medicinal plants used in Indian traditional medicine have proven to be safe, but information on herb-herb or herb-drug interaction is not readily available. The drug-drug or herb-drug interactions mechanism involves inhibition of cytochrome P450 (CYP450) enzyme. Approximately, 90% of the drugs or herbs are metabolized through CYP450 system. Many CYP isozymes were discovered and identified and among them CYP3A4 (50%) and CYP2D6 (25%) isozymes are most important as they are responsible for 75% of the CYP-mediated metabolism [21] . In addition to inhibition of cytochrome P450, other drugs or herbs may up-regulate CYP450, increasing CYP450-mediated metabolism. The present study was initiated to investigate the effects of P. foetida, a well-known herb, and its phytochemical constituent lupeol on hepatic phase I drug metabolizing enzyme, namely CYP3A4 and CYP2D6, to determine the safety profile of this herb.
The qualitative analysis of the ethanolic, petroleum ether, chloroform, acetone, and benzene extracts along with a pure compound lupeol was performed. The TLC study showed that lupeol was present in the ethanolic extract in sufficient quantity. Several distinct bands present in the ethanolic extract were observed in developed TLC plate after post chromatography derivatization ( Figure 1 ). One distinct band of the TLC plate was matched with standard lupeol and found to have Rf value of 0.40 ( Figure 2 ). Based upon our result, the triterpenoid lupeol seems to be a major component of the P. foetida ethanolic extract. Lupeol is also present as a major component in other plants, showing a wide variety of pharmacological activities, such as antimicrobial [21] and cytotoxic effects [22] as well as interaction with another drug [23] .
The in vitro assay was performed to measure the inhibitory potential of P. foetida ethanolic extract and lupeol on pooled rat liver microsomes at the preliminary stage. The protein concentration of NPC Natural Product Communications 2017 Vol. 12 No. 9 1401 -1404 isolated rat liver microsomes was found to be 12.48 mg/mL, whereas the CYP450 concentration of rat liver microsomes was found to be 0.512 nM/mg protein. Various concentrations of microsomes were used in this work. Rat liver microsomes were incubated with 100 μg/mL of ethanolic extract, lupeol (a component of the ethanolic extract) and ketoconazole (a known inhibitor). The ethanolic extract showed 45±3.3% inhibition of rat liver microsomes, whereas the lupeol showed 44±3.8% inhibition ( Figure  3 ). However, the plant extract and lupeol showed significantly less inhibition (74±5.4%) than that of known inhibitor ketoconazole. A fluorometric assay was used to measure the effects of P. foetida ethanolic extract and lupeol (0.5 to100 μg/mL) on hepatic CYP isozymes, such as CYP3A4 and CYP2D6. For CYP3A4, the extract and lupeol showed inhibition of enzyme activity in a concentrationdependent fashion (Figure 4 ). However, these results were of lesser magnitude compared to that of known inhibitor ketoconazole ( Figure 4 ). Similar results were obtained for another isozyme CYP2D6 ( Figure 5 ). As presented in Table 1 , the extract has higher IC 50 values for both isozymes comparable to the known inhibitors ketoconazole and quinidine.
As the use of herbal medicinal products continues to grow, public health issues and concerns surrounding their safety are also increasingly recognized. In this regard the quality of herbals specifically the optimal quantity and quality of bioactive constituents present in it is very important as they have the potential to cause interactions with various classes of drugs [22] . Use of herbs as medicines from natural sources is increasing rapidly. Many reports claim that due to herb-drug interaction, morbidity and even mortality occurs [23] . Values are expressed as mean±SD (n=3). *P<0.05 was compared to ketoconazole and quinidine.
The hepatic P450 enzymes are known to be involved in the metabolism of majority of the drugs. The induction and inhibition of CYPs have been considered as the major mechanism of metabolic drug-drug interactions [24] . Active constituents present in plant extracts may inhibit or induce drug metabolizing enzymes, Paederia foetida and CYP Natural Product Communications Vol. 12 (9) 2017 1403 resulting in severe herb-drug interaction. Inhibition of these metabolizing enzymes may affect pharmacological activity and also cause drug-induced toxicity [25] . Here, we evaluated the impact of an ethanolic extract of medicinal plant P. foetida and its one major constituent lupeol on hepatic CYP-mediated drug metabolism. We observed that the extract and lupeol showed less enzyme inhibition than known inhibitors (ketoconazole and quinidine). CYP3A4 and CYP2D6 are among the main drug-metabolizing enzymes responsible for the metabolism of 75% of drugs available in the market [26, 27] . Drugs metabolized by CYPs are prone to drug-drug interactions modifying their response [28] . Hepatic damage occurs when CYP3A inhibitors are administered in concomitant with terfenadine, astemizole, cisapride, or pimozide [29] . However, herbdrug interaction studies like ours have several limitations. An in vitro study requires higher doses than the clinical uses. Poor bioavailability aspect should be taken into consideration. We used only one isolated constituent whereas the herbal extract contains many metabolites. Human genetic polymorphism is another important part which merits further attention.
In conclusion, our study revealed that P. foetida extract and lupeol were weak inhibitors of two key CYP isozymes, namely CYP3A4 and CYP2D6. Therefore, it may be safe to use P. foetida in respect to two tested key CYP450 isozymes. Nevertheless, several important aspects, such as co-administration of herb and drug, mechanism-based enzyme inhibition, and undesirable interactions with proteins as well as enzymes, need to be addressed in the future for better understanding of complete safety profile of P. foetida. Preparation of the extract: The freshly collected plant material was washed, shade-dried (25-30°C) and then milled to coarse powder. The powdered plant material (2 kg) was extracted with ethanol at room temperature for 48 h. The extract was dried under reduced pressure at 45°C to yield a crude ethanolic extract (3.47%). The extract was suspended in water and fractioned successively with petroleum ether, chloroform, acetoneand benzene. Then, theextracts were evaporated under reduced pressure in rotatory evaporator and lyophilized to yield petroleum ether (2.18%), chloroform (1.02%), acetone (1.24%), and benzene (3.76%) extract.
High performance thin layer chromatographic analysis:
Chromatographic analysis was performed using HPTLC (CAMAG Scientific Inc., Wilmington, NC, USA). ~50 mg of each extract was used for preparation of spotting samples in 2 mL respective solvent used for the extraction. Individual plant extracts (10 µl) were spotted onto the precoated plates using a Linomat 5 application system. Lupeol (5, 10, 15 and 20 mg/mL) was employed as a marker triterpenoid to detect the presence of lupeol in different extracts. The triterpenoid was separated using benzene and ethyl acetate (9:1) as a mobile phase. The spots developed were visualized under Camag TLC scanner III (580 nm) and were digitized using CAMAG photo documentation system.
Preparation of samples:
The lyophilized extract of P. foetida was solubilized in ethanol to obtain a concentration of 1 mg/mL. Lupeol (1 mg/mL) was dissolved in ethanol. Ketoconazole (10 mM) was used as a positive control to compare the inhibitory activity. Microsome without extract was used as the negative control. The ethyl alcohol was used as solvent for the CYP450 assay and had no inhibition with spectral absorption while the solvent effect was neutralized by deionized water. [30] . Further, it was subjected to ultracentrifugation at 105,000 x g for 1 h at 4°C and the microsomal fraction (105,000 x g pellet) was collected. It was resuspended in 1.15% KCl solution and stored at -80°C for future use. Protein concentrations were determined by the biuret method.
Preparation of rat liver microsomes:

CYP-carbon monoxide complex assay:
The CYP450-CO complex assay was performed with pooled rat liver microsomes as per the method of Ahmmed et al. [30] . Percentage of inhibition was calculated as per the method described by Pandit et al. [25] .
Fluorometric assay: The fluorometric assay method performed in this study was described by Ahmmed et al. [22] . 144 μL NADPH-Co factor mixture were added to each well of the first row of 96microtitre well plates. Then, 100 μL cofactor mixture was added to the remaining wells except the blank wells. Then, 6 μL of ethanolic extract was added to the first row of each well. Two-fold serial dilutions were made and the plates were incubated for 10 min at 37°C. Ethanolic solution of quinidine (1 μM) and ketoconazole (10 μM) were used as known standard inhibitors of CYP2D6 and CYP3A4, respectively. 100 μL of the enzyme-substrate solution in phosphate buffer was used to initiate the reaction. 10 μM of 7benzyloxymethyloxy-3-cyanocoumarin and 10 μM of ethoxymethyloxy-3-cyanocoumarin were used as substrate for CYP3A4 and for CYP2D6, respectively. The fluorescence intensities of the metabolites were measured by a SpectraMax® M5 multi-mode microplate reader (VWR, Atlanta, GA, USA) using an emission and excitation wavelength of 460 nm and 390 nm for CYP2D6 and 530 nm and 409 nm for CYP3A4, respectively. All samples were assayed in triplicate. The percentage of inhibition and IC 50 were calculated as described by Pandit et al. [25] .
Statistical analysis: All samples were assayed in triplicate and the results are shown as mean±standard deviation. The data were analyzed by one way analysis of variance followed by Dunnet t-test and P values less than 0.05 were considered significant.
